Use of N-nitrosodimethylamine (NDMA) contaminated valsartan products and risk of cancer¶
Pottegård, A., Kristensen, K. B., Ernst, M. T., Johansen, N. B., Quartarolo, P., & Hallas, J. (2018). Use of N-nitrosodimethylamine (NDMA) contaminated valsartan products and risk of cancer: Danish nationwide cohort study. BMJ.
Cited by¶
1 citation across 1 artifact.
Each citation links to the sentence it supports in the citing article.
Domain-specific¶
- Returns Friction
- When the blood-pressure drug valsartan was found in 2018 to contain the probable carcinogen NDMA
This sourceReports that valsartan, an antihypertensive, was discovered in July 2018 to be contaminated with NDMA, which IARC classifies as probably carcinogenic to humans.
SupportedVerified against the work's full text
“Valsartan is an angiotensin II receptor antagonist used to treat hypertension and heart failure.”
- When the blood-pressure drug valsartan was found in 2018 to contain the probable carcinogen NDMA
Verification¶
Does it exist? Confirmed. This work's DOI resolves to a registered record, which fixes its identity. That is all it fixes.
Does it back the claim? Read against the text for 1 of 1 citation: 1 supported. Each verdict is shown under its citation below, with what in the work backs the sentence.
Support is checked per citation rather than per work — the same source can be cited soundly in one article and wrongly in another. Per-citation recording began recently, so a citation with no recorded check is a gap in the record rather than evidence it went unchecked.
See how references were verified.
Registry ID ref:6b8b56ea940f · see in the full table